CompanyHealth
Epirium Bio
Epirium Bio is a San Diego-based clinical-stage biopharmaceutical company developing orally available small molecules that target PGE2 signaling to restore tissue homeostasis, reduce inflammation, and stimulate regeneration. Its lead candidate, MF-300, is a first-in-class oral 15-PGDH enzyme inhibitor advancing toward a Phase 2b trial for sarcopenia, the age-related loss of muscle strength for which no FDA-approved therapy currently exists.
2008Founded
San DiegoHQ
$85 millionSeries A
biotechbiopharmaceuticalsarcopenia15-pgdhpge2drug-discovery
